SOURCE: NanoVibronix, Inc.

NanoVibronix, Inc.

September 06, 2016 07:30 ET

NanoVibronix Receives Health Canada Approval to Sell UroShield™ in Canada

ELMSFORD, NY--(Marketwired - September 06, 2016) - NanoVibronix, Inc, (OTCQB: NAOV), a medical device company, today announced that NanoVibronix has received clearance to sell the UroShield™ in Canada. UroShield™ is effective in preventing Urinary Tract Infections (UTI) in patients with indwelling urinary catheters. Catheter-associated urinary tract infections (CAUTIs) is one of the leading nosocomial complications which cause patient morbidity and mortality. Prolonged urinary catheterization adds substantially to the cost of medical care. The UroShield™ system is a multi-targeting solution intended to work against a number of factors that are essential in preventing catheter related complications. The UroShield™ reduces pain and discomfort associated with urinary catheter use, decreases catheter related trauma, diminishes bacteriuria by prevention of biofilm formation and increases antibiotic efficacy.

William Stern, Ph.D. Chief Executive Officer of NanoVibronix, stated, "We are very pleased with Health Canada's approval to sell the UroShield™ in Canada. There are millions of urinary catheters used in hospitals every year. Most patients who have a chronic need for indwelling catheters will get infected with a UTI after a few weeks. In addition, patients who have indwelling catheters as part of surgical procedures in hospitals also suffer the same risk. UTIs are generally difficult to manage, however the UroShield™ not only prevents UTIs but also reduces the pain associated with urinary catheters. We are also currently conducting a double blinded clinical trial for UroShield™ in the U.S. in order to obtain 510(k) clearance from the U.S. Food and Drug Administration."

About NanoVibronix
NanoVibronix Inc. is a medical device company headquartered in Elmsford, NY with research and development in Nesher, Israel, that is focused on developing medical devices utilizing its proprietary and patented low intensity surface acoustic wave technology. The company's groundbreaking technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications. The devices accelerate wound healing and provide pain relief. The devices can also be administered at home, without the assistance of medical professionals. The company's products include PainShield® and WoundShield™, which both have CE Mark. The PainShield™ also has FDA clearance. NanoVibronix's catheter based products include the UroShield™ and NG-Shield™ that are both CE Marked. Additional information about the company is available at: www.nanovibronix.com.

SAFE HARBOR STATEMENT: This release contains certain statements that are, or may be deemed to be, forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934, and are made in reliance upon the protections provided by such Acts for forward-looking statements. We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form SEC filings.

Contact Information

  • Investor Relations Contacts:
    Rodd Leeds or Natalya Rudman
    Crescendo Communications, LLC
    Email: naov@crescendo-ir.com
    Tel: 212-671-1020